Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 18/20 | 0.67 |
| ▸ | FAAH | O00519 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175226 | 1.00 | MGLL (0.67) | MGLLFAAHHPGDRBP4 | |
| SCHEMBL14877434 | 0.92 | MGLL (0.79) | MGLLFAAHHPGD | |
| SCHEMBL2731685 | 0.92 | MGLL (0.79) | MGLLFAAHHPGD | |
| SCHEMBL14877244 | 0.89 | MGLL (0.67) | MGLLFAAHHPGDRBP4 | |
| SCHEMBL14877405 | 0.89 | MGLL (0.67) | MGLLFAAHHPGDRBP4 | |
| SCHEMBL697821 | 0.89 | MGLL (0.85) | MGLLFAAH | |
| SCHEMBL2729343 | 0.87 | MGLL (0.65) | MGLLFAAHHPGDRBP4 | |
| SCHEMBL14877233 | 0.84 | MGLL (0.60) | MGLLFAAHHPGD | |
| SCHEMBL14877006 | 0.83 | MGLL (0.56) | MGLLFAAHHPGDRBP4 | |
| SCHEMBL14877123 | 0.82 | MGLL (0.46) | MGLLFAAHHPGDRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-19 | — | — | US | disclosed |
| US-8513423-B2 | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20130102584-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102584-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | MGLL 3/4885FAAH 86/4885HPGD 1282/4885 |
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885FAAH 91/4885HPGD 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.